Method for the determination of anti-drug antibodies against an effector function suppressed human or humanized drug antibody

Patent metadata

Field	Value
Publication number	US-11340234-B2
Application number	US-201715587730-A
Country	US
Kind code	B2
Filing date	May 5, 2017
Priority date	Nov 5, 2014
Publication date	May 24, 2022
Grant date	May 24, 2022

Abstract

Herein is reported an anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody against an effector function suppressed human or humanized drug antibody in a sample comprising the incubation of a sample comprising mammalian blood serum with full length human Fcgamma receptor I or an Fc-region binding fragment thereof so that a complex between the anti-drug antibody against the effector function suppressed human or humanized drug antibody present in the sample and the human Fcgamma receptor I or the Fc-region binding fragment thereof forms, whereby the full length human Fcgamma receptor I or the Fc-region binding fragment thereof is conjugated to a detectable label, and the determination of the formed complex by the detectable label.

First claim

What is claimed is:

1. An anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody against an effector function suppressed human or humanized drug antibody in a sample comprising the following steps in the following order:
a. Incubating a sample comprising mammalian blood serum with full length human Fcgamma receptor I or an Fc-binding region of full-length human Fcgamma I so that a complex between the anti-drug antibody against the effector function suppressed human or humanized drug antibody present in the sample and the human Fcgamma receptor I or the Fc-binding region of full-length human Fcgamma I forms, whereby the full length human Fcgamma receptor I or the Fc-binding region of full-length human Fcgamma I is conjugated to a detectable label;
b. isolating the complex formed between the anti-drug antibody against the effector function suppressed human or humanizued drug antibody and the human Fcgamma receptor I or the Fc-binding region of full-length human Fcgamma I; and
c. determining the complex by the detectable label.

2. An anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody (ADA) against an effector function suppressed human or humanized drug antibody (EFS-DA) in a sample comprising the following steps in the following order:
a. incubating a solid phase on which the effector function suppressed human or humanized drug antibody has been immobilized with a sample comprising mammalian blood serum so that a solid-phase-bound drug antibody-anti-drug antibody complex is formed;
b. incubating the solid phase to which the drug antibody-anti-drug antibody complex formed in step a. is bound with full length human Fcgamma receptor I or an Fc-binding region of full-length human Fcgamma I, whereby the full length human Fcgamma receptor I or the Fc-binding region of full-length human Fcgamma I is conjugated to a detectable label; and
c. determining the formation of a solid-phase-bound complex in step b. by determining the presence of the detectable label; and
d. wherein determining the presence of the detectable label in step c. indicates the presence of an antidrug antibody against an effector function suppressed human or humanized drug antibody in the sample.

3. An anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody (ADA) against an effector function suppressed human or humanized drug antibody (EFS-DA) in a sample comprising the following steps in the following order:
a. incubating a solid phase on which the FAB (Fragment-Antigen Binding) of an effector function suppressed human or humanized drug antibody has been immobilized with a sample comprising mammalian blood serum so that a solid-phase-bound FAB-anti-drug antibody complex is formed;
b. incubating the solid phase (to which the FAB-anti-drug antibody complex formed in step a. is bound) with full length human Fcgamma receptor I or an Fc-binding region of full-length human Fcgamma I, whereby the full length human Fcgamma receptor I or the Fc-binding region of full-length human Fcgamma I is conjugated to a detectable label; and
c. determining the formation of a solid-phase bound complex in step b. by determining the presence of the detectable label and thereby determining the presence of an antidrug antibody against an effector function suppressed human.

4. An anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody (ADA) against an effector function suppressed human or humanized drug antibody (EFS-DA) in a sample comprising the following steps in the following order:
a. adding (excess) drug antibody to the sample (to transfer (any) anti-drug antibody present in the sample in a drug-antibody-anti-drug antibody complex), wherein the sample comprises mammalian blood serum;
b. incubating a solid phase on which the antigen to which the EFS-DA specifically binds has been immobilized with the sample obtained in step a. (so that a solid-phase-bound antigen-drug antibody-anti-drug antibody complex is formed),
c. incubating the solid phase (to which the antigen-drug antibody-anti-drug antibody complex formed in step b. is bound) with full length human Fcgamma receptor I or an Fc-binding region of full-length human Fcgamma I, whereby the full length human Fcgamma receptor I or the Fc-binding region of full-length human Fcgamma I is conjugated to a detectable label; and
d. determining the formation of a solid-phase-bound complex in step c. by determining the presence of the detectable label and thereby determining the presence of an antidrug antibody against an effector function suppressed human or humanized drug antibody in the sample.

5. An anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody (ADA) against an effector function suppressed human or humanized drug antibody (EFS-DA) in a sample comprising the following steps in the following order:
a. adding (excess) drug antibody to the sample (to transfer (any) anti-drug antibody present in the sample in a drug-antibody-anti-drug antibody complex), wherein the sample comprises mammalian blood serum;
b. incubating a solid phase on which full length human Fcgamma receptor I or an Fc-binding region of full-length human Fcgamma I has been immobilized with the sample obtained in step a. (so that a solid-phase-bound receptor-drug antibody-anti-drug antibody complex is formed);
c. incubating the solid phase (to which the receptor-drug antibody-anti-drug antibody complex formed in step b) is bound) with the antigen of the drug antibody, whereby the antigen is conjugated to a detectable label; and
d. determining the formation of a solid-phase-bound complex in step c. by determining the presence of the detectable label and thereby determining the presence of an antidrug antibody against an effector function suppressed human or humanized drug antibody in the sample.

6. An anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody (ADA) against an effector function suppressed human or humanized drug antibody (EFS-DA) in a sample comprising the following steps in the following order:
a. adding (excess) drug antibody to the sample (to transfer (any) anti-drug antibody present in the sample in a drug-antibody-anti-drug antibody complex), wherein the sample comprises mammalian blood serum;
b. incubating a solid phase on which an anti-drug antibody against the drug antibody has been immobilized with the sample obtained in step a. (so that a solid-phase-bound anti-drug antibody-drug antibody-anti-drug antibody complex is formed);
c. incubating the solid phase (to which the anti-drug antibody-drug antibody-anti-drug antibody complex formed in step b. is bound) with full length human Fcgamma receptor I or an Fc-binding region of full-length human Fcgamma I, whereby the full length human Fcgamma receptor I or the Fc-binding region of full-length human Fcgamma I is conjugated to a detectable label; and
d. determining the formation of a solid-phase-bound complex in step c. by determining the presence of the detectable label and thereby determining the presence of an anti-drug antibody against an effector function suppressed human or humanized drug antibody in the sample.

7. The immunoassay according to claim 2 , wherein each incubating step is followed by washing the solid phase to remove unbound compounds.

8. The immunoassay according to claim 2 , wherein the assay is for the determination of the presence and the amount of an anti-drug antibody (ADA) against an effector function suppressed human or humanized drug antibody (EFS-DA) in a sample and comprises the further steps: determining the formation of a solid-phase-bound complex in the previous s

Assignees

• Hoffmann La Roche

Inventors

• Umana Pablo
• Wessels Uwe
• Stubenrauch Kay-Gunnar

Classifications

• G01N33/58

  involving labelled substances (G01N33/53 takes precedence) · CPC title

• G01N33/6854 Primary

  Immunoglobulins · CPC title

• G01N33/543

  with an insoluble carrier for immobilising immunochemicals · CPC title

• G01N33/5306

  Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding · CPC title

• G01N33/537

  with separation of immune complex from unbound antigen or antibody · CPC title